BACKGROUND: The Child-Pugh (CP) class is a commonly used scoring system to measure liver function in patients with hepatocellular carcinoma (HCC). We correlate the Albumin-Bilirubin (ALBI) grading system and CP to overall survival in our HCC patients receiving radioembolization. METHODS: We retrospectively evaluated patients who received radioembolization for HCC between the years 2009-2014. We evaluated the albumin and bilirubin levels in our patients prior to receiving their first (n=124) radioembolization. The ALBI grades were calculated from these data with the formula (log10 bilirubin ×0.66) + (albumin × -0.085) and correlated to outcomes using Mantel-Cox Log analysis. These statistical comparisons were duplicated with CP classes. RESULTS: Median survival differences between CP class A and B and between ALBI grade 1 and 2 were 4.7 and 9.9 months, respectively. A subset of ALBI grades 1 and 2 were identified within our CP class A patients with a median survival difference of 9.9 months. CONCLUSIONS: ALBI is a more sensitive marker of liver function than CP in the setting of mild dysfunction. Using ALBI, we identified a subset of patients that have significantly better outcomes from Y-90 radioembolization than previously identified with CP.
BACKGROUND: The Child-Pugh (CP) class is a commonly used scoring system to measure liver function in patients with hepatocellular carcinoma (HCC). We correlate the Albumin-Bilirubin (ALBI) grading system and CP to overall survival in our HCC patients receiving radioembolization. METHODS: We retrospectively evaluated patients who received radioembolization for HCC between the years 2009-2014. We evaluated the albumin and bilirubin levels in our patients prior to receiving their first (n=124) radioembolization. The ALBI grades were calculated from these data with the formula (log10 bilirubin ×0.66) + (albumin × -0.085) and correlated to outcomes using Mantel-Cox Log analysis. These statistical comparisons were duplicated with CP classes. RESULTS: Median survival differences between CP class A and B and between ALBI grade 1 and 2 were 4.7 and 9.9 months, respectively. A subset of ALBI grades 1 and 2 were identified within our CP class A patients with a median survival difference of 9.9 months. CONCLUSIONS: ALBI is a more sensitive marker of liver function than CP in the setting of mild dysfunction. Using ALBI, we identified a subset of patients that have significantly better outcomes from Y-90 radioembolization than previously identified with CP.
Authors: Anthony W H Chan; Takshi Kumada; Hidenori Toyoda; Toshifumi Tada; Charing C N Chong; Frankie K F Mo; Winnie Yeo; Philip J Johnson; Paul B S Lai; Anthony T C Chan; Ka-Fai To; Stephen L Chan Journal: J Gastroenterol Hepatol Date: 2016-07 Impact factor: 4.029
Authors: Ravi Murthy; Rodolfo Nunez; Janio Szklaruk; William Erwin; David C Madoff; Sanjay Gupta; Kamran Ahrar; Michael J Wallace; Alan Cohen; Douglas M Coldwell; Andrew S Kennedy; Marshall E Hicks Journal: Radiographics Date: 2005-10 Impact factor: 5.333
Authors: Anthony W H Chan; Charing C N Chong; Frankie K F Mo; John Wong; Winnie Yeo; Philip J Johnson; Shuangni Yu; Paul B S Lai; Anthony T C Chan; Ka-Fai To; Stephen L Chan Journal: J Gastroenterol Hepatol Date: 2017-01 Impact factor: 4.029
Authors: Julien Edeline; Jean-Frédéric Blanc; Philip Johnson; Boris Campillo-Gimenez; Paul Ross; Yuk Ting Ma; Judy King; Richard A Hubner; Kate Sumpter; Suzanne Darby; Jeff Evans; Chinenye Iwuji; Daniel Swinson; Peter Collins; Kinnari Patel; Iqtedar Muazzam; Daniel H Palmer; Tim Meyer Journal: Liver Int Date: 2016-06-22 Impact factor: 5.828
Authors: Yazan Abuodeh; Arash O Naghavi; Kamran A Ahmed; Puja S Venkat; Youngchul Kim; Bela Kis; Junsung Choi; Benjamin Biebel; Jennifer Sweeney; Daniel A Anaya; Richard Kim; Mokenge Malafa; Jessica M Frakes; Sarah E Hoffe; Ghassan El-Haddad Journal: World J Gastroenterol Date: 2016-12-21 Impact factor: 5.742
Authors: Rucha M Shah; Sarah Sheikh; Jimmy Shah; Elaina Vivian; Alejandro Mejia; Islam Shahin; Parvez S Mantry Journal: J Gastrointest Oncol Date: 2021-08
Authors: Philippe d'Abadie; Stephan Walrand; Renaud Lhommel; Michel Hesse; Ivan Borbath; François Jamar Journal: Curr Oncol Date: 2022-03-29 Impact factor: 3.109
Authors: Antoine Azar; Zlatko Devcic; Ricardo Paz-Fumagalli; Lucas Lauar Cortizo Vidal; J Mark McKinney; Gregory Frey; Andrew R Lewis; Charles Ritchie; Jason S Starr; Kabir Mody; Beau Toskich Journal: J Gastrointest Oncol Date: 2020-08
Authors: Giovanni Marasco; Luigina Vanessa Alemanni; Antonio Colecchia; Davide Festi; Franco Bazzoli; Giuseppe Mazzella; Marco Montagnani; Francesco Azzaroli Journal: J Clin Med Date: 2021-05-08 Impact factor: 4.241